Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. ASCO Annual Meeting 2019, abstract LBA9015.
Hyperbarezuurstoftherapie voor late toxiciteit na radiotherapie voor borstkanker
apr 2024 | Borstkanker, Radiotherapie